Targeting Wnt Canonical Signaling by Recombinant sFRP1 Bound Luminescent Au-Nanocluster Embedded Nanoparticles in Cancer Theranostics

ACS Biomaterials Science and Engineering

Volumn 1, Issue 12, 2015, Pages 1256-1266

  Ghoshal, Archita ^a   Goswami, Upashi ^a   Sahoo, Amaresh Kumar ^a   Chattopadhyay, Arun ^a   Ghosh, Siddhartha Sankar ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

cancer cotherapy; gold nanocluster; nanoparticle; secreted frizzled related protein 1 (sFRP1); Wnt signaling pathway

Indexed keywords

ALGINIC ACID; BETA CATENIN; CHITOSAN; CISPLATIN; CYCLIN D1; GOLD NANOPARTICLE; PROTEIN HYDROLYSATE; RECOMBINANT PROTEIN; RECOMBINANT SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 1; SURVIVIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COMPOSITE MATERIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUMINESCENCE; NANOFABRICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; THERANOSTIC NANOMEDICINE; WNT SIGNALING PATHWAY;

EID: 84969134495     PISSN: None     EISSN: 23739878     Source Type: Journal    
DOI: 10.1021/acsbiomaterials.5b00305     Document Type: Article

References (60)

1. Zhen, Z.; Tang, W.; Chen, H.; Lin, X.; Todd, T.; Wang, G.; Cowger, T.; Chen, X.; Xie, J. RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors ACS Nano 2013, 7, 4830-4837 10.1021/nn305791q
2. Gu, Z.; Biswas, A.; Zhao, M.; Tang, Y. Tailoring nanocarriers for intracellular protein delivery Chem. Soc. Rev. 2011, 40, 3638-3655 10.1039/c0cs00227e
3. Ramu, A.; Glaubiger, D.; Fuks, Z. Reversal of Acquired Resistance to Doxorubicin in P388 Murine Leukemia Cells by Tamoxifen and Other Triparanol Analogues Cancer Res. 1984, 44, 4392-4395
4. O'Brien, M. E. R.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Annals of Oncology 2004, 15, 440-449 10.1093/annonc/mdh097
5. Florea, A.-M.; Büsselberg, D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects Cancers 2011, 3, 1351-1371 10.3390/cancers3011351
6. Mathé, G.; Amiel, J. L.; Schwarzenberg, L.; Schneider, M.; Cattan, A.; Schlumberger, J. R.; Hayat, M.; De Vassal, F. ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA Lancet 1969, 293, 697-699 10.1016/S0140-6736(69)92648-8
7. Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer J. Immunol. 2014, 192, 5451-8 10.4049/jimmunol.1490019
8. Chacon, J. A.; Sarnaik, A. A.; Chen, J. Q.; Creasy, C.; Kale, C.; Robinson, J.; Weber, J.; Hwu, P.; Pilon-Thomas, S.; Radvanyi, L. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy Clin. Cancer Res. 2015, 21, 611-21 10.1158/1078-0432.CCR-14-1934
9. Giles, R. H.; van Es, J. H.; Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer Biochim. Biophys. Acta, Rev. Cancer 2003, 1653, 1-24 10.1016/S0304-419X(03)00005-2
10. Anastas, J. N.; Moon, R. T. WNT signalling pathways as therapeutic targets in cancer Nat. Rev. Cancer 2013, 13, 11-26 10.1038/nrc3419
11. Lee, A. Y.; He, B.; You, L.; Dadfarmay, S.; Xu, Z.; Mazieres, J.; Mikami, I.; McCormick, F.; Jablons, D. M. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma Oncogene 2004, 23, 6672-6 10.1038/sj.onc.1207881
12. Suzuki, H.; Gabrielson, E.; Chen, W.; Anbazhagan, R.; van Engeland, M.; Weijenberg, M. P.; Herman, J. G.; Baylin, S. B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer Nat. Genet. 2002, 31, 141-9 10.1038/ng892
13. Marsit, C. J.; Karagas, M. R.; Andrew, A.; Liu, M.; Danaee, H.; Schned, A. R.; Nelson, H. H.; Kelsey, K. T. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer Cancer Res. 2005, 65, 7081-5 10.1158/0008-5472.CAN-05-0267
14. Hu, E.; Zhu, Y.; Fredrickson, T.; Barnes, M.; Kelsell, D.; Beeley, L.; Brooks, D. Tissue restricted expression of two human Frzbs in preadipocytes and pancreas Biochem. Biophys. Res. Commun. 1998, 247, 287-93 10.1006/bbrc.1998.8784
15. Caldwell, G. M.; Jones, C.; Gensberg, K.; Jan, S.; Hardy, R. G.; Byrd, P.; Chughtai, S.; Wallis, Y.; Matthews, G. M.; Morton, D. G. The Wnt antagonist sFRP1 in colorectal tumorigenesis Cancer Res. 2004, 64, 883-8 10.1158/0008-5472.CAN-03-1346
16. Veeck, J.; Niederacher, D.; An, H.; Klopocki, E.; Wiesmann, F.; Betz, B.; Galm, O.; Camara, O.; Durst, M.; Kristiansen, G.; Huszka, C.; Knuchel, R.; Dahl, E. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis Oncogene 2006, 25, 3479-88 10.1038/sj.onc.1209386
17. Takada, T.; Yagi, Y.; Maekita, T.; Imura, M.; Nakagawa, S.; Tsao, S. W.; Miyamoto, K.; Yoshino, O.; Yasugi, T.; Taketani, Y.; Ushijima, T. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers Cancer Sci. 2004, 95, 741-4 10.1111/j.1349-7006.2004.tb03255.x
18. Fukui, T.; Kondo, M.; Ito, G.; Maeda, O.; Sato, N.; Yoshioka, H.; Yokoi, K.; Ueda, Y.; Shimokata, K.; Sekido, Y. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer Oncogene 2005, 24, 6323-7 10.1038/sj.onc.1208777
19. Yang, Z. Q.; Liu, G.; Bollig-Fischer, A.; Haddad, R.; Tarca, A. L.; Ethier, S. P. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers Int. J. Cancer 2009, 125, 1613-21 10.1002/ijc.24518
20. Shih, Y. L.; Hsieh, C. B.; Lai, H. C.; Yan, M. D.; Hsieh, T. Y.; Chao, Y. C.; Lin, Y. W. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway Int. J. Cancer 2007, 121, 1028-35 10.1002/ijc.22750
21. Ghoshal, A.; Ghosh, S. S. Expression, Purification, and Therapeutic Implications of Recombinant sFRP1 Appl. Biochem. Biotechnol. 2015, 175, 2087-103 10.1007/s12010-014-1354-8
22. Richardson, T. P.; Murphy, W. L.; Mooney, D. J. Polymeric delivery of proteins and plasmid DNA for tissue engineering and gene therapy Crit. Rev. Eukaryotic Gene Expression 2001, 11, 47-58 10.1615/CritRevEukarGeneExpr.v11.i1-3.30
23. Singh, A. K.; Hahn, M. A.; Gutwein, L. G.; Rule, M. C.; Knapik, J. A.; Moudgil, B. M.; Grobmyer, S. R.; Brown, S. C. Multi-dye theranostic nanoparticle platform for bioimaging and cancer therapy Int. J. Nanomed. 2012, 7, 2739-2750 10.2147/IJN.S28357
24. Bardhan, R.; Lal, S.; Joshi, A.; Halas, N. J. Theranostic Nanoshells: From Probe Design to Imaging and Treatment of Cancer Acc. Chem. Res. 2011, 44, 936-946 10.1021/ar200023x
25. Ghosh, R.; Goswami, U.; Ghosh, S. S.; Paul, A.; Chattopadhyay, A. Synergistic Anticancer Activity of Fluorescent Copper Nanoclusters and Cisplatin Delivered through a Hydrogel Nanocarrier ACS Appl. Mater. Interfaces 2015, 7, 209-22 10.1021/am505799q
26. Ma, L. L.; Feldman, M. D.; Tam, J. M.; Paranjape, A. S.; Cheruku, K. K.; Larson, T. A.; Tam, J. O.; Ingram, D. R.; Paramita, V.; Villard, J. W.; Jenkins, J. T.; Wang, T.; Clarke, G. D.; Asmis, R.; Sokolov, K.; Chandrasekar, B.; Milner, T. E.; Johnston, K. P. Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy ACS Nano 2009, 3, 2686-96 10.1021/nn900440e
27. Bian, P.; Zhou, J.; Liu, Y.; Ma, Z. One-step fabrication of intense red fluorescent gold nanoclusters and their application in cancer cell imaging Nanoscale 2013, 5, 6161-6 10.1039/c3nr01282d
28. Shiang, Y.-C.; Huang, C.-C.; Chen, W.-Y.; Chen, P.-C.; Chang, H.-T. Fluorescent gold and silver nanoclusters for the analysis of biopolymers and cell imaging J. Mater. Chem. 2012, 22, 12972-12982 10.1039/c2jm30563a
29. Tian, D.; Qian, Z.; Xia, Y.; Zhu, C. Gold Nanocluster-Based Fluorescent Probes for Near-Infrared and Turn-On Sensing of Glutathione in Living Cells Langmuir 2012, 28, 3945-3951 10.1021/la204380a
30. Retnakumari, A.; Setua, S.; Menon, D.; Ravindran, P.; Muhammed, H.; Pradeep, T.; Nair, S.; Koyakutty, M. Molecular-receptor-specific, non-toxic, near-infrared-emitting Au cluster-protein nanoconjugates for targeted cancer imaging Nanotechnology 2010, 21, 055103 10.1088/0957-4484/21/5/055103
31. Wu, X.; He, X.; Wang, K.; Xie, C.; Zhou, B.; Qing, Z. Ultrasmall near-infrared gold nanoclusters for tumor fluorescence imaging in vivo Nanoscale 2010, 2, 2244-9 10.1039/c0nr00359j
32. Wang, C.; Li, J.; Amatore, C.; Chen, Y.; Jiang, H.; Wang, X.-M. Gold Nanoclusters and Graphene Nanocomposites for Drug Delivery and Imaging of Cancer Cells Angew. Chem., Int. Ed. 2011, 50, 11644-11648 10.1002/anie.201105573
33. Lin, C.-A. J.; Yang, T.-Y.; Lee, C.-H.; Huang, S. H.; Sperling, R. A.; Zanella, M.; Li, J. K.; Shen, J.-L.; Wang, H.-H.; Yeh, H.-I.; Parak, W. J.; Chang, W. H. Synthesis, Characterization, and Bioconjugation of Fluorescent Gold Nanoclusters toward Biological Labeling Applications ACS Nano 2009, 3, 395-401 10.1021/nn800632j
34. Bian, P.; Zhou, J.; Liu, Y.; Ma, Z. One-step fabrication of intense red fluorescent gold nanoclusters and their application in cancer cell imaging Nanoscale 2013, 5, 6161-6166 10.1039/c3nr01282d
35. Sahoo, A. K.; Banerjee, S.; Ghosh, S. S.; Chattopadhyay, A. Simultaneous RGB Emitting Au Nanoclusters in Chitosan Nanoparticles for Anticancer Gene Theranostics ACS Appl. Mater. Interfaces 2014, 6, 712-724 10.1021/am4051266
36. Zhang, X.-D.; Chen, J.; Luo, Z.; Wu, D.; Shen, X.; Song, S.-S.; Sun, Y.-M.; Liu, P.-X.; Zhao, J.; Huo, S.; Fan, S.; Fan, F.; Liang, X.-J.; Xie, J. Radiosensitizers: Enhanced Tumor Accumulation of Sub-2 nm Gold Nanoclusters for Cancer Radiation Therapy (Adv. Healthcare Mater. 1/2014) Adv. Healthcare Mater. 2014, 3, 152-152 10.1002/adhm.201470006
37. Zhang, A.; Tu, Y.; Qin, S.; Li, Y.; Zhou, J.; Chen, N.; Lu, Q.; Zhang, B. Gold nanoclusters as contrast agents for fluorescent and X-ray dual-modality imaging J. Colloid Interface Sci. 2012, 372, 239-44 10.1016/j.jcis.2012.01.005
38. Chen, A. M.; Zhang, M.; Wei, D.; Stueber, D.; Taratula, O.; Minko, T.; He, H. Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells Small 2009, 5, 2673-2677 10.1002/smll.200900621
39. Solal-Céligny, P.; Lepage, E.; Brousse, N.; Tendler, C. L.; Brice, P.; Haïoun, C.; Gabarre, J.; Pignon, B.; Tertian, G.; Bouabdallah, R.; Rossi, J. F.; Doyen, C.; Coiffier, B. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial J. Clin. Oncol. 1998, 16, 2332-8
40. Banerjee, S.; Sahoo, A. K.; Chattopadhyay, A.; Ghosh, S. S. Hydrogel nanocarrier encapsulated recombinant I[small kappa]B[small alpha] as a novel anticancer protein therapeutics RSC Adv. 2013, 3, 14123-14131 10.1039/c3ra23181j
41. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D. M. Therapeutic Nanoparticles for Drug Delivery in Cancer Clin. Cancer Res. 2008, 14, 1310-1316 10.1158/1078-0432.CCR-07-1441
42. Leamon, C. P.; Reddy, J. A. Folate-targeted chemotherapy Adv. Drug Delivery Rev. 2004, 56, 1127-41 10.1016/j.addr.2004.01.008
43. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol. Rev. 2002, 54, 561-87 10.1124/pr.54.4.561
44. Lakowicz, J. R. Principles of Fluorescence Spectroscopy; Springer: New York, 2006; pp 54-55.
45. Surana, R.; Sikka, S.; Cai, W.; Shin, E. M.; Warrier, S. R.; Tan, H. J.; Arfuso, F.; Fox, S. A.; Dharmarajan, A. M.; Kumar, A. P. Secreted frizzled related proteins: Implications in cancers Biochim. Biophys. Acta, Rev. Cancer 2014, 1845, 53-65 10.1016/j.bbcan.2013.11.004
46. Ugolini, F.; Charafe-Jauffret, E.; Bardou, V. J.; Geneix, J.; Adelaide, J.; Labat-Moleur, F.; Penault-Llorca, F.; Longy, M.; Jacquemier, J.; Birnbaum, D.; Pebusque, M. J. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type Oncogene 2001, 20, 5810-7 10.1038/sj.onc.1204706
47. Liu, C.; Li, N. A. N.; Lu, H.; Wang, Z.; Chen, C.; Wu, L. I. N.; Liu, J.; Lu, Y.; Wang, F. Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal square cell carcinoma Biomed. Rep. 2015, 3, 123-127 10.3892/br.2014.388
48. Ricketts, C. J.; Hill, V. K.; Linehan, W. M. Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project PLoS One 2014, 9, e85621 10.1371/journal.pone.0085621
49. Albanese, A.; Tang, P. S.; Chan, W. C. The effect of nanoparticle size, shape, and surface chemistry on biological systems Annu. Rev. Biomed. Eng. 2012, 14, 1-16 10.1146/annurev-bioeng-071811-150124
50. Remunán-López, C.; Bodmeier, R. Mechanical, water uptake and permeability properties of crosslinked chitosan glutamate and alginate films J. Controlled Release 1997, 44, 215-225 10.1016/S0168-3659(96)01525-8
51. Le Guevel, X.; Daum, N.; Schneider, M. Synthesis and characterization of human transferrin-stabilized gold nanoclusters Nanotechnology 2011, 22, 275103 10.1088/0957-4484/22/27/275103
52. Vernejoul, F.; Ghenassia, L.; Souque, A.; Lulka, H.; Drocourt, D.; Cordelier, P.; Pradayrol, L.; Pyronnet, S.; Buscail, L.; Tiraby, G. Gene Therapy Based on Gemcitabine Chemosensitization Suppresses Pancreatic Tumor Growth Mol. Ther. 2006, 14, 758-767 10.1016/j.ymthe.2006.07.010
53. Fine, H. A.; Dear, K. B. G.; Loeffler, J. S.; Mc Black, P. L.; Canellos, G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 1993, 71, 2585-2597 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S
54. James, N. D.; Hussain, S. A.; Hall, E.; Jenkins, P.; Tremlett, J.; Rawlings, C.; Crundwell, M.; Sizer, B.; Sreenivasan, T.; Hendron, C.; Lewis, R.; Waters, R.; Huddart, R. A. Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer N. Engl. J. Med. 2012, 366, 1477-1488 10.1056/NEJMoa1106106
55. Moore, D. H.; Ali, S.; Koh, W.-J.; Michael, H.; Barnes, M. N.; McCourt, C. K.; Homesley, H. D.; Walker, J. L. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: A gynecologic oncology group study Gynecol. Oncol. 2012, 124, 529-533 10.1016/j.ygyno.2011.11.003
56. Cairncross, G.; Berkey, B.; Shaw, E.; Jenkins, R.; Scheithauer, B.; Brachman, D.; Buckner, J.; Fink, K.; Souhami, L.; Laperierre, N.; Mehta, M.; Curran, W. Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J. Clin. Oncol. 2006, 24, 2707-2714 10.1200/JCO.2005.04.3414
57. Peters, W. A.; Liu, P. Y.; Barrett, R. J.; Stock, R. J.; Monk, B. J.; Berek, J. S.; Souhami, L.; Grigsby, P.; Gordon, W.; Alberts, D. S. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix J. Clin. Oncol. 2000, 18, 1606-1613
58. Miles, D.; von Minckwitz, G.; Seidman, A. D. Combination versus sequential single-agent therapy in metastatic breast cancer Oncologist 2003, 7 (Suppl 6) 13-9 10.1634/theoncologist.8-1-124
59. Sorenson, C. M.; Barry, M. A.; Eastman, A. Analysis of Events Associated With Cell Cycle Arrest at G2 Phase and Cell Death Induced by Cisplatin Journal of the National Cancer Institute 1990, 82, 749-755 10.1093/jnci/82.9.749
60. Ju, S. M.; Pae, H. O.; Kim, W. S.; Kang, D. G.; Lee, H. S.; Jeon, B. H. Role of reactive oxygen species in p53 activation during cisplatin-induced apoptosis of rat mesangial cells European review for medical and pharmacological sciences 2014, 18, 1135-41